Bristol Myers Squibb Co. closed $2.39 below its 52-week high ($61.08), which the company reached on November 11th.

Some of the world's largest hedge funds are hiring doctors, scientists and analysts to give them expert insight into the ...

Bristol-Myers Squibb can probably continue to grow for a long time. Its dividend looks to be sustainable at the moment. But ...

Bristol Myers Squibb (BMY) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the ...

Bristol Myers Squibb has enlisted three-year-old Massachusetts biotech AI Proteins to use its artificial intelligence-driven ...

Bristol Myers Squibb became the latest large drugmaker to sue the federal government over a plan to change how it doles out ...

We recently published a list of 10 Stocks That Are Close To Becoming Dividend Aristocrats. In this article, we are going to ...

The moves will affect more than 300 employees across both companies as both firms look to drive growth in the long term.

Despite billions poured into research, new medicines still typically take a decade or more to develop.

There is more to the comparison, and in the sections below, we discuss why we think BMY will outperform JNJ in the next three ...

Bristol Myers Squibb Co. is challenging a federal health agency for denying its plan to implement a rebate model for its ...